WO2012078703A3 - Inhibiting chromosome instability in ovarian cancer - Google Patents

Inhibiting chromosome instability in ovarian cancer Download PDF

Info

Publication number
WO2012078703A3
WO2012078703A3 PCT/US2011/063634 US2011063634W WO2012078703A3 WO 2012078703 A3 WO2012078703 A3 WO 2012078703A3 US 2011063634 W US2011063634 W US 2011063634W WO 2012078703 A3 WO2012078703 A3 WO 2012078703A3
Authority
WO
WIPO (PCT)
Prior art keywords
ovarian cancer
chromosome instability
cell
protein
methods
Prior art date
Application number
PCT/US2011/063634
Other languages
French (fr)
Other versions
WO2012078703A2 (en
Inventor
Timothy J. Yen
Haomin Huang
Original Assignee
Fox Chase Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fox Chase Cancer Center filed Critical Fox Chase Cancer Center
Publication of WO2012078703A2 publication Critical patent/WO2012078703A2/en
Publication of WO2012078703A3 publication Critical patent/WO2012078703A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods for reducing chromosome instability in an ovarian cancer cell comprise inhibiting the expression or biologic activity of protein phosphatase 1 or KNL-1 in the cell or expressing a fusion protein comprising inner centromere protein or Aurora B kinase and a polypeptide comprising the kinetochore binding domain of centromere protein B in the cell. Methods for treating ovarian cancer comprise reducing chromosome instability in ovarian cancer cells in an ovarian cancer patient, and administering to the patient an effective amount of a chemotherapeutic agent.
PCT/US2011/063634 2010-12-08 2011-12-07 Inhibiting chromosome instability in ovarian cancer WO2012078703A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42090210P 2010-12-08 2010-12-08
US61/420,902 2010-12-08

Publications (2)

Publication Number Publication Date
WO2012078703A2 WO2012078703A2 (en) 2012-06-14
WO2012078703A3 true WO2012078703A3 (en) 2014-04-24

Family

ID=46207697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/063634 WO2012078703A2 (en) 2010-12-08 2011-12-07 Inhibiting chromosome instability in ovarian cancer

Country Status (1)

Country Link
WO (1) WO2012078703A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130297A2 (en) * 2015-01-21 2016-08-18 Memorial Sloan-Kettering Cancer Center Methods and compositions for increasing susceptibility to radiation treatment by inhibiting suppression of numerical chromosomal instability of cancer cells
CN111410683B (en) * 2020-03-10 2020-12-04 南京林业大学 Antigenic polypeptide of poplar functional centromere histone CENH3 and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620875A (en) * 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
US20060105915A1 (en) * 1999-06-30 2006-05-18 Marker Gene Technologies, Inc. Compositions and methods for targeted enzymatic release of cell regulatory compounds
US20090010952A1 (en) * 2006-09-08 2009-01-08 Obeid Michel Sarkis Pharmaceutical compound for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt or erp57 translocation
US20090048159A1 (en) * 2006-09-08 2009-02-19 Obeid Michel Sarkis Kit for treating a health condition by inducing translocation of a calreticulin protein to a cellular membrane
US20100048687A1 (en) * 2007-01-22 2010-02-25 Roger Nitsch Use of phosphatase inhibitors for the treatment of neurodegenerative diseases
US20100166657A1 (en) * 2003-06-06 2010-07-01 Medimmune, Llc USE OF EphA4 AND MODULATOR OF EphA4 FOR DIAGNOSIS, TREATMENT AND PREVENTION OF CANCER

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620875A (en) * 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
US20060105915A1 (en) * 1999-06-30 2006-05-18 Marker Gene Technologies, Inc. Compositions and methods for targeted enzymatic release of cell regulatory compounds
US20100166657A1 (en) * 2003-06-06 2010-07-01 Medimmune, Llc USE OF EphA4 AND MODULATOR OF EphA4 FOR DIAGNOSIS, TREATMENT AND PREVENTION OF CANCER
US20090010952A1 (en) * 2006-09-08 2009-01-08 Obeid Michel Sarkis Pharmaceutical compound for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt or erp57 translocation
US20090048159A1 (en) * 2006-09-08 2009-02-19 Obeid Michel Sarkis Kit for treating a health condition by inducing translocation of a calreticulin protein to a cellular membrane
US20100048687A1 (en) * 2007-01-22 2010-02-25 Roger Nitsch Use of phosphatase inhibitors for the treatment of neurodegenerative diseases

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BAJIC ET AL.: "THE EFFECT OF PACLITAXEL ALONE AND IN COMBINATION WITH CYCLOHEXIMIDE ON THE FREQUENCY OF PREMATURE CENTROMERE DIVISION IN VITRO.", ARCH. BIOL. SCI., vol. 62, no. 1, April 2010 (2010-04-01), BELGRADE, pages 63 - 74 *
EGLOFF ET AL.: "Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1.", EMBO J., vol. 16, no. 8, 1997, pages 1876 - 1887, XP002037247, doi:10.1093/emboj/16.8.1876 *
GANEM ET AL.: "A Mechanism Linking Extra Centrosomes to Chromosomal Instability.", NATURE., vol. 460, no. 7252, 2009, pages 278 - 282 *
HERBERT: "Link unraveled between chromosomal instability and centrosome defects in cancer cells", EUREKALERT, 7 June 2009 (2009-06-07), Retrieved from the Internet <URL:http://www.eurekalert.org/pubreleases/2009-O6/dci-Iub060509.php> [retrieved on 20120305] *
HOLLAND ET AL.: "Boveri revisited: Chromosomal instability, aneuploidy and tumorigenesis.", NAT REV MOL CELL BIOL., vol. 10, no. 7, 2009, pages 478 - 487 *
KIM ET AL.: "Aurora kinases and protein phosphatase 1 mediate chromosome congression through regulation of CENP-E.", CELL., vol. 142, no. 3, August 2010 (2010-08-01), pages 444 - 455, XP028931181, doi:10.1016/j.cell.2010.06.039 *
LEE ET AL.: "Tautomycetin inhibits growth of colorectal cancer cells through p21 cip/WAF1 induction via the extracellular signal?regulated kinase pathway.", MOL CANCER THER., vol. 5, no. 12, 2006, pages 3222 - 31 *
LIU ET AL.: "Regulated targeting of protein phosphatase 1 to the outer kinetochore by KNL1 opposes Aurora B kinase.", J CELL BIOL., vol. 188, no. 6, March 2010 (2010-03-01), pages 809 - 820 *
LONG ET AL.: "Inhibition of protein phosphatase-1 is linked to phosphorylation of p53 and apoptosis.", APOPTOSIS., vol. 7, no. 1, 2002, pages 31 - 9 *
MITSUHASHI ET AL.: "Usage of Tautomycetin, a Novel Inhibitor of Protein Phosphatase 1 (PP1), ), Reveals That PP1 Is a Positive Regulator of Raf-1 in Vivo.", J BIOL CHEM., vol. 278, no. 1, 2003, pages 82 - 8 *

Also Published As

Publication number Publication date
WO2012078703A2 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
MX2022010490A (en) Compositions and methods for internalizing enzymes.
PH12018500394A1 (en) Pd-l1 (&#34;programmed death-ligand 1&#34;) antibodies
AU2018201942B2 (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
MX2015000428A (en) Compositions and methods for regulating car t cells.
MX2015005963A (en) Heterocyclic glutaminase inhibitors.
WO2014096965A3 (en) Novel heterocyclic compounds as bromodomain inhibitors
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
MX2016001587A (en) Kdm1a inhibitors for the treatment of disease.
WO2014031487A8 (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
MX2010010317A (en) Novel heterocyclic compounds and uses therof.
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
WO2013036850A3 (en) Modulation of midbody derivatives
MX2013012387A (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri).
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
WO2012160333A3 (en) Recombinant yeast expressing human h- ferritin
SG182629A1 (en) Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
EP2279002A4 (en) Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same
WO2014041088A3 (en) Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
MX2014010714A (en) Procaspase combination therapy for glioblastoma.
WO2013131089A3 (en) Potent anticancer activity via dual compound activation
EP3687546A4 (en) Compositions and methods for treating heart disease via redirected t cell immunotherapies
Genaro-Mattos et al. Correction: Antioxidant Activity of Caffeic Acid against Iron-Induced Free Radical Generation—A Chemical Approach
MX370688B (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell.
WO2012078703A3 (en) Inhibiting chromosome instability in ovarian cancer
IN2014DN09437A (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11847583

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 11847583

Country of ref document: EP

Kind code of ref document: A2